ALLO חוב לטווח קצר של החברה Allogene Corp

This daily price chart for Allogene Therapeutics (ALLO) illustrates debt dynamics, which currently stand at 0.01. The current stage of clinical trials limits the impact on drug pricing; however, future innovations will ensure high margins. The firm's operations rely on developing cutting-edge oncology treatments, while Allogene Therapeutics (ALLO) controls the entire technological process through its own high-tech manufacturing facility in the US.

This indicator assesses the issuer's solvency through the lens of obligations maturing within one year. By analyzing the company's short-term liabilities, an investor determines liquidity risk and dependence on external refinancing. The metric aggregates current loans and trade payables to identify hidden pressure on capital. For Allogene Therapeutics (ALLO), this is critical due to FDA regulatory pauses. Restricting the inflow of funds during the development of CAR-T therapy makes the control of current debts a prerequisite for the ecosystem's survival.